SMMT experienced dramatic financial deterioration with net losses increasing 388% to over $1 billion while burning through operating cash at an accelerated rate despite raising additional capital.
The company appears to be in a critical cash-burning phase typical of late-stage biotech development, with operating cash outflows more than doubling to $323M annually. While they successfully raised capital (evidenced by increased cash position and share count rising from 738M to 775M shares), the burn rate acceleration combined with billion-dollar losses suggests they may need additional funding sooner than expected.
The financial picture shows a company aggressively scaling operations with total assets growing 73% to $751M and cash increasing 115% to $225M, indicating successful capital raising. However, this growth came with severe cash burn acceleration as operating cash outflows more than doubled to $323M and net losses exploded 388% to over $1B, while interest expense surged 1,466% suggesting increased debt financing. The combination of rapid asset growth funded by equity and debt, paired with dramatically worsening operating performance, signals a company in intensive late-stage development mode that will likely need additional capital within the next 12-18 months.
Interest expense surged 1466.2% — significant debt increase or rising rates materially impacting earnings.
Net income declined 387.8% — review whether driven by operations, interest costs, or non-recurring items.
Capital expenditure jumped 372.7% — major investment cycle underway; assess returns on deployment.
Operating cash flow fell 127.2% — earnings quality concerns; investigate working capital changes and non-cash items.
Cash position surged 114.8% — strong cash generation or capital raise providing significant financial cushion.
Liabilities grew 97.2% — significant increase in debt or obligations, assess impact on financial flexibility.
Current liabilities surged 74.9% — significant near-term obligations; verify ability to meet short-term debt.
Asset base grew 72.5% — expansion through organic growth, acquisitions, or capital deployment.
Current assets grew 70% — improving short-term liquidity or inventory/receivables build.
Equity base grew 69.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →